Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 1
1967 1
1968 3
1969 2
1970 8
1971 3
1972 3
1973 12
1974 12
1975 10
1976 11
1977 8
1978 9
1979 17
1980 15
1981 20
1982 24
1983 29
1984 18
1985 33
1986 26
1987 27
1988 25
1989 22
1990 15
1991 13
1992 10
1993 8
1994 11
1995 7
1996 9
1997 8
1998 6
1999 7
2000 3
2001 2
2002 2
2003 5
2004 3
2005 2
2006 6
2007 7
2008 2
2009 1
2010 3
2011 3
2012 5
2013 8
2014 5
2015 6
2017 2
2018 2
2020 3
2021 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for flufenazin depot
Your search for flufenan-depot retrieved no results
The pharmacokinetics of long-acting antipsychotic medications.
Spanarello S, La Ferla T. Spanarello S, et al. Curr Clin Pharmacol. 2014;9(3):310-7. doi: 10.2174/15748847113089990051. Curr Clin Pharmacol. 2014. PMID: 23343447 Review.
Such medication is useful in patients who do not reliably take their oral medication. The pharmacokinetics and clinical actions of various depot formulations of antipsychotic drugs have been extensively studied. The clinical pharmacokinetics of the depot antipsychot …
Such medication is useful in patients who do not reliably take their oral medication. The pharmacokinetics and clinical actions of various …
Depot fluphenazine for schizophrenia.
Adams CE, Eisenbruch M. Adams CE, et al. Cochrane Database Syst Rev. 2000;(2):CD000307. doi: 10.1002/14651858.CD000307. Cochrane Database Syst Rev. 2000. PMID: 10796340 Updated. Review.
OBJECTIVES: To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia. ...The use of depot fluphenazine continues to be based on clinical judgement rather than evidence from methodical evaluation within trials. …
OBJECTIVES: To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia. ...The use of …
Bromperidol decanoate (depot) for schizophrenia.
Purgato M, Adams CE. Purgato M, et al. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD001719. doi: 10.1002/14651858.CD001719.pub3. Cochrane Database Syst Rev. 2011. PMID: 21901678 Updated. Review.
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. ...SELECTION CRITERIA: We sought all randomised tr …
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic prepa …
Bromperidol decanoate (depot) for schizophrenia.
Purgato M, Adams CE. Purgato M, et al. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001719. doi: 10.1002/14651858.CD001719.pub4. Cochrane Database Syst Rev. 2012. PMID: 23152208 Free PMC article. Review.
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. ...SELECTION CRITERIA: We sought all randomised tr …
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic prepa …
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Maayan N, et al. Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Cochrane Database Syst Rev. 2015. PMID: 25654768 Free PMC article. Review.
SELECTION CRITERIA: We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations. ...No significant difference was …
SELECTION CRITERIA: We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphe …
Depot bromperidol decanoate for schizophrenia.
Wong D, Adams CE, David A, Quraishi SN. Wong D, et al. Cochrane Database Syst Rev. 2004;(3):CD001719. doi: 10.1002/14651858.CD001719.pub2. Cochrane Database Syst Rev. 2004. PMID: 15266450 Updated. Review.
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. ...SELECTION CRITERIA: All randomised trials focus …
OBJECTIVES: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic prepa …
Depot fluphenazine decanoate and enanthate for schizophrenia.
David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. David A, et al. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000307. doi: 10.1002/14651858.CD000307. Cochrane Database Syst Rev. 2005. PMID: 15674872 Updated. Review.
Fluphenazine decanoate does not reduce relapse more than oral neuroleptics (n=419, 6 RCTs, RR relapse 26-52 weeks 1.46 CI 0.8 to 2.8) or other depot antipsychotics (n=581, 11 RCTs, RR relapse 26-52 weeks 0.82 CI 0.6 to 1.2). ...For fluphenazine enanthate ther …
Fluphenazine decanoate does not reduce relapse more than oral neuroleptics (n=419, 6 RCTs, RR relapse 26-52 weeks 1.46 CI 0.8 to 2.8) …
Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ. Kirson NY, et al. J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19. J Clin Psychiatry. 2013. PMID: 23842008 Free article. Review.
OBJECTIVE: Nonadherence is a major challenge in schizophrenia treatment. While long-acting (depot) antipsychotic medications are often recommended to address adherence problems, evidence on the comparative effectiveness of depot versus oral antipsychotics is inconsi …
OBJECTIVE: Nonadherence is a major challenge in schizophrenia treatment. While long-acting (depot) antipsychotic medications are ofte …
Clinical pharmacokinetics of the depot antipsychotics.
Jann MW, Ereshefsky L, Saklad SR. Jann MW, et al. Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003. Clin Pharmacokinet. 1985. PMID: 2864156 Review.
The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine enanthate and decanoate, haloperidol decanoate, clopenthixol decanoate and flupenthixol decanoate) are reviewed. ...Cigarette smoking has been …
The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine en …
Neuroleptic plasma levels.
Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Van Putten T, et al. Schizophr Bull. 1991;17(2):197-216. doi: 10.1093/schbul/17.2.197. Schizophr Bull. 1991. PMID: 1679251 Review.
Therapeutic plasma level ranges, in which good antipsychotic effect occurs without undue side effects, have been tentatively identified for perphenazine, haloperidol, fluphenazine, and chlorpromazine. The extent to which aberrantly high plasma levels are associated with in …
Therapeutic plasma level ranges, in which good antipsychotic effect occurs without undue side effects, have been tentatively identified for …
508 results